Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies
出版年份 2018 全文链接
标题
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies
作者
关键词
Clinical trial, JAK1 protein tyrosine kinase, JAK2 protein tyrosine kinase, Pancreatic neoplasms
出版物
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-03-06
DOI
10.1007/s10637-018-0580-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer
- (2017) Jacob M. Smigiel et al. MOLECULAR CANCER RESEARCH
- Loss of P53 Function Activates JAK2–STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival
- (2016) Sonja M. Wörmann et al. GASTROENTEROLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma
- (2016) Aino Salmiheimo et al. PLoS One
- Abstract 1336: Novel immunotherapeutic activity of JAK and PI3Kδ inhibitors in a model of pancreatic cancer
- (2015) Holly K. Koblish et al. CANCER RESEARCH
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- (2015) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Host systemic inflammatory response influences outcome in pancreatic cancer
- (2015) Clem W. Imrie PANCREATOLOGY
- TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis
- (2015) Jesse Gore et al. Oncotarget
- Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
- (2014) Viktoria Manstein et al. Current Signal Transduction Therapy
- Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?
- (2014) Evan J Walker WORLD JOURNAL OF GASTROENTEROLOGY
- Pancreatic cancer cachexia: a review of mechanisms and therapeutics
- (2014) Carlyn R. Tan et al. Frontiers in Physiology
- The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
- (2012) Donald C. McMillan CANCER TREATMENT REVIEWS
- Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
- (2012) J. Mascarenhas et al. CLINICAL CANCER RESEARCH
- Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
- (2012) J. Mascarenhas et al. CURRENT MEDICINAL CHEMISTRY
- Ruxolitinib for the treatment of myelofibrosis: its clinical potential
- (2012) Srdan Verstovsek et al. Therapeutics and Clinical Risk Management
- A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma
- (2011) Nigel B. Jamieson et al. ANNALS OF SURGICAL ONCOLOGY
- Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
- (2011) Marina Lesina et al. CANCER CELL
- Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
- (2011) Kristine H. Allin et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started